Nelivaptan (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nelivaptan" in Serbian language version.

refsWebsite

Global rank Serbian rank

4^th place

8^th place

2^nd place

4^th place

195^th place

154^th place

1^st place

low place

doi.org

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). „Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders”. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370—5. PMC 122955 . PMID 11959912. doi:10.1073/pnas.092012099.
Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). „An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders”. CNS drug reviews. 11 (1): 53—68. PMID 15867952. doi:10.1111/j.1527-3458.2005.tb00035.x.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). „Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders”. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370—5. PMC 122955 . PMID 11959912. doi:10.1073/pnas.092012099.
Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). „An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders”. CNS drug reviews. 11 (1): 53—68. PMID 15867952. doi:10.1111/j.1527-3458.2005.tb00035.x.

„Second-quarter 2008 results” (PDF). Press Release. Sanofi-Aventis. 31. 07. 2008. Архивирано из оригинала (PDF) 06. 12. 2008. г. Приступљено 10. 06. 2009. „It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).”

„Second-quarter 2008 results” (PDF). Press Release. Sanofi-Aventis. 31. 07. 2008. Архивирано из оригинала (PDF) 06. 12. 2008. г. Приступљено 10. 06. 2009. „It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).”